TY - JOUR T1 - M2 Macrophage Marker Chitinase 3-Like 2 (CHI3L2) Associates With Progression of Conventional Renal Cell Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 6939 LP - 6943 DO - 10.21873/anticanres.13915 VL - 39 IS - 12 AU - CSABA PUSZTAI AU - MARIA V. YUSENKO AU - DANIEL BANYAI AU - ARPAD SZANTO AU - GYULA KOVACS Y1 - 2019/12/01 UR - http://ar.iiarjournals.org/content/39/12/6939.abstract N2 - Background/Aim: In spite of early detection, appoximately 15% of the small renal cell carcinomas (RCC) will develop metastasis within 5 years follow-up. The aim of this study was to identify new biomarkers to estimate the postoperative relapse of the most common conventional RCC. Patients and Methods: Tissue multi arrays of conventional RCC without metastasis at the time of operation from a cohort of 634 patients were analysed by immunohistochemistry for expression of the chitinase 3-like protein 2 (CHI3L2). Cancer specific survival of patients was estimated with Kaplan–Meier analysis, univariate and multivariate Cox regression models. Results: Kaplan–Meier analysis estimated a shorter cancer-free survival for patients with CHI3L2 positive tumors. In multivariate analysis, the CHI3L2 positivity associated with a 3.5 times higher risk for tumor relapse (p<0.001). Conclusion: Expression of CHI3L2 in tumor cells of conventional RCC define a group of patients at high risk for postoperative progression. ER -